Mechanisms and implications of cancer cell dormancy in head and neck carcinoma

doi:10.7518/hxkq.2018.01.018

Abstract

Abstract:

Disease metastasis and relapse in many cancer patients several years (even decades) after surgical remission have been recently acknowledged as cases of cancer dormancy. Although cases of minimal residual disease are well documented, knowledge on its biological mechanisms and clinical implications remains limited. To date, numerous reviews have summarized the three potential models that may explain this phenomenon, including the angiogenic, immunologic, and cellular dormancy. In this study, we discuss newly uncovered mechanisms governing tumor cell dormancy in head and neck cancer, emphasizing on the crosstalk between dormant tumor cells and their microenvironments. Additionally, we explore the mechanisms on the reactivation of dormant residual tumor cells in anatomical sites, including the lymph nodes and bone marrow.

Key words: cancer dormancy, disseminated tumor cell, head and neck cancer, hypoxia, lymph-node metastasis

CLC Number:

R739.8

Xiaolei Gao, Xinhua Liang, Yaling Tang. Mechanisms and implications of cancer cell dormancy in head and neck carcinoma[J]. West China Journal of Stomatology, 2018, 36(1): 92-98.

References 41

[1]	Willis RA.The spread of tumours in the human body[M]. London: Butterworth＆Co, 1934:447.
[2]	Hadfield G.The dormant cancer cell[J]. Br Med J, 1954, 2(4888):607-610.
[3]	Aguirre-Ghiso JA.Models, mechanisms and clinical evi-dence for cancer dormancy[J]. Nat Rev Cancer, 2007, 7(11):834-846.
[4]	Yeh AC, Ramaswamy S.Mechanisms of cancer cell dor-mancy-another hallmark of cancer[J]. Cancer Res, 2015, 75(23):5014-5022.
[5]	Pantel K, Brakenhoff RH, Brandt B.Detection, clinical rele-vance and specific biological properties of disseminating tumour cells[J]. Nat Rev Cancer, 2008, 8(5):329-340.
[6]	Campton DE, Ramirez AB, Nordberg JJ, et al.High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining[J]. BMC Cancer, 2015, 15:360.
[7]	Moghbeli M, Moghbeli F, Forghanifard MM, et al.Cancer stem cell detection and isolation[J]. Med Oncol, 2014, 31(9):69.
[8]	Fukusumi T, Ishii H, Konno M, et al.CD10 as a novel mar-ker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma[J]. Br J Cancer, 2014, 111(3):506-514.
[9]	Chaffer CL, Weinberg RA.A perspective on cancer cell metastasis[J]. Science, 2011, 331(6024):1559-1564.
[10]	Chakraborty C, Chin KY, Das S. miRNA-regulated cancer stem cells: understanding the property and the role of miRNA in carcinogenesis[J]. Tumour Biol, 2016, 37(10):13039-13048.
[11]	Yata K, Beder LB, Tamagawa S, et al.MicroRNA expression profiles of cancer stem cells in head and neck squamous cell carcinoma[J]. Int J Oncol, 2015, 47(4):1249-1256.
[12]	Sun Z, Hu W, Xu J, et al.MicroRNA-34a regulates epithelial-mesenchymal transition and cancer stem cell phenotype of head and neck squamous cell carcinoma in vitro[J]. Int J Oncol, 2015, 47(4):1339-1350.
[13]	Masuda M, Wakasaki T, Toh S.Stress-triggered atavistic reprogramming (STAR) addiction: driving force behind head and neck cancer[J]. Am J Cancer Res, 2016, 6(6): 1149-1166.
[14]	Aguirre-Ghiso JA, Ossowski L, Rosenbaum SK.Green fluo-rescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of path-way activation during primary and metastatic growth[J]. Cancer Res, 2004, 64(20):7336-7345.
[15]	Chéry L, Lam HM, Coleman I, et al.Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways[J]. Oncotarget, 2014, 5(20):9939-9951.
[16]	Sosa MS, Avivar-Valderas A, Bragado P, et al.ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease[J]. Clin Cancer Res, 2011, 17(18):5850-5857.
[17]	Mazar AP, Ahn RW, O’Halloran TV.Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic[J]. Curr Pharm Des, 2011, 17(19):1970-1978.
[18]	Knopeke MT, Ritschdorff ET, Clark R, et al.Building on the foundation of daring hypotheses: using the MKK4 me-tastasis suppressor to develop models of dormancy and me-tastatic colonization[J]. FEBS Lett, 2011, 585(20):3159-3165.
[19]	Humtsoe JO, Kramer RH.Differential epidermal growth factor receptor signaling regulates anchorage-independent growth by modulation of the PI3K/AKT pathway[J]. Onco-gene, 2010, 29(8):1214-1226.
[20]	Picon A, Gold LI, Wang J, et al.A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta1[J]. Cancer Epidemiol Biomarkers Prev, 1998, 7(6):497-504.
[21]	Ghajar CM, Peinado H, Mori H, et al.The perivascular niche regulates breast tumourdormancy[J]. Nat Cell Biol, 2013, 15(7):807-817.
[22]	Bragado P, Estrada Y, Parikh F, et al.TGF-β2 dictates disse-minated tumour cell fate in target organs through TGF-β-RⅢ and p38α/β signalling[J]. Nat Cell Biol, 2013, 15(11):1351-1361.
[23]	Yumoto K, Eber MR, Wang J, et al.Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow[J]. Sci Rep, 2016, 6:36520.
[24]	Wendt MK, Taylor MA, Schiemann BJ, et al.Down-regu-lation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer[J]. Mol Biol Cell, 2011, 22(14):2423-2435.
[25]	Denys H, Derycke L, Hendrix A, et al.Differential impact of TGF-beta and EGF on fibroblast differentiation and in-vasion reciprocally promotes colon cancer cell invasion[J]. Cancer Lett, 2008, 266(2):263-274.
[26]	Kobayashi A, Okuda H, Xing F, et al.Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone[J]. J Exp Med, 2011, 208(13):2641-2655.
[27]	Buijs JT, Henriquez NV, van Overveld PG, et al. TGF-beta and BMP7 interactions in tumour progression and bone metastasis[J]. Clin Exp Metastasis, 2007, 24(8):609-617.
[28]	Hjertner O, Hjorth-Hansen H, Börset M, et al.Bone mor-phogenetic protein-4 inhibits proliferation and induces apop-tosis of multiple myeloma cells[J]. Blood, 2001, 97(2):516-522.
[29]	Lu X, Mu E, Wei Y, et al.VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast can-cer by engaging α4β1-positive osteoclast progenitors[J]. Cancer Cell, 2011, 20(6):701-714.
[30]	Sosa MS, Parikh F, Maia AG, et al.NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes[J]. Nat Commun, 2015, 6:6170.
[31]	Jung Y, Decker AM, Wang J, et al.Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow[J]. Oncotarget, 2016, 7(18):25698-25711.
[32]	Ono M, Kosaka N, Tominaga N, et al. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells[J]. Sci Signal, 2014,7(332):ra63.
[33]	Bartosh TJ, Ullah M, Zeitouni S, et al.Cancer cells enter dormancy after cannibalizing mesenchymal stem/stromal cells (MSCs)[J]. Proc Natl Acad Sci U S A, 2016, 113(42):E6447-E6456.
[34]	Eckers JC, Kalen AL, Sarsour EH, et al.Forkhead box M1 regulates quiescence-associated radioresistance of human head and neck squamous carcinoma cells[J]. Radiat Res, 2014, 182(4):420-429.
[35]	Msaki A, Pastò A, Curtarello M, et al.A hypoxic signature marks tumors formed by disseminated tumor cells in the BALB-neuT mammary cancer model[J]. Oncotarget, 2016, 7(22):33081-33095.
[36]	Weidenfeld K, Schif-Zuck S, Abu-Tayeh H, et al.Dormant tumor cells expressing LOXL2 acquire a stem-like pheno-type mediating their transition to proliferative growth[J]. Oncotarget, 2016, 7(44):71362-71377.
[37]	Johnson RW, Finger EC, Olcina MM, et al.Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow[J]. Nat Cell Biol, 2016, 18(10):1078-1089.
[38]	Ameri K, Jahangiri A, Rajah AM, et al.HIGD1A regulates oxygen consumption, ROS production, and AMPK activity during glucose deprivation to modulate cell survival and tumor growth[J]. Cell Rep, 2015, 10(6):891-899.
[39]	Beasley NJ, Prevo R, Banerji S, et al.Intratumorallymphangiogenesis and lymph node metastasis in head and neck cancer[J]. Cancer Res, 2002, 62(5):1315-1320.
[40]	De Cock JM, Shibue T, Dongre A, et al.Inflammation trig-gers Zeb1-dependent escape from tumor latency[J]. Cancer Res, 2016, 76(23):6778-6784.
[41]	EI Touny LH, Vieira A, Mendoza A, et al.Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells[J]. J Clin Invest, 2014, 124(1):156-168.